Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Untch

Showing results (21-30 of 377) with videos related to

Pageof 38
Sort By:
Oncology (Williston Park, N.Y.)|March 8, 2012
What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer?Gunter Von Minckwitz, Sibylle Loibl, Michael Untch
Breast Care (Basel, Switzerland)|September 9, 2010
Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast CancerNadia Harbeck, Volker Heinemann, Sibylle Loibl, et al.
Deutsches Arzteblatt International|September 18, 2015
Breast Reconstruction Following Cancer TreatmentBernd Gerber, Mario Marx, Michael Untch, et al.
Deutsches Arzteblatt International|May 7, 2016
In ReplyBernd Gerber, Mario Marx, Michael Untch, et al.
Psychotherapie, Psychosomatik, Medizinische Psychologie|June 29, 2006
[Prophylactic mastectomy in women at high risk for breast and ovarian cancer: qualitative analysis of the decision making process and long-term satisfaction of two women carrying a BRCA1-mutation]Andrea Vodermaier, Ingo Bauerfeind, Michael Untch, et al.
Breast (Edinburgh, Scotland)|October 22, 2011
Lessons from the neoadjuvant setting on how best to choose adjuvant therapiesGunter von Minckwitz, Sibylle Loibl, Andrea Maisch, et al.
Oncology Research and Treatment|December 9, 2014
Predictive factors for response to neoadjuvant therapy in breast cancerSibylle Loibl, Gunter von Minckwitz, Michael Untch, et al.
Oncology and Therapy|May 31, 2021
How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast CancerMichael Untch, Miguel Martin, Michelino De Laurentiis, et al.
Seminars in Oncology|June 8, 2004
Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropeniaLaura Biganzoli, Michael Untch, Tomas Skacel, et al.
Gynakologisch-Geburtshilfliche Rundschau|April 10, 2004
[Sentinel lymph node biopsy in breast cancer: state of the art]Ingo Bauerfeind, Isabelle Himsl, Thorsten Kühn, et al.
Pageof 38

Showing results (21-30 of 377) with videos related to

Sort By:
Pageof 38
Oncology (Williston Park, N.Y.)|March 8, 2012
What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer?Gunter Von Minckwitz, Sibylle Loibl, Michael Untch
Breast Care (Basel, Switzerland)|September 9, 2010
Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast CancerNadia Harbeck, Volker Heinemann, Sibylle Loibl, et al.
Deutsches Arzteblatt International|September 18, 2015
Breast Reconstruction Following Cancer TreatmentBernd Gerber, Mario Marx, Michael Untch, et al.
Deutsches Arzteblatt International|May 7, 2016
In ReplyBernd Gerber, Mario Marx, Michael Untch, et al.
Psychotherapie, Psychosomatik, Medizinische Psychologie|June 29, 2006
[Prophylactic mastectomy in women at high risk for breast and ovarian cancer: qualitative analysis of the decision making process and long-term satisfaction of two women carrying a BRCA1-mutation]Andrea Vodermaier, Ingo Bauerfeind, Michael Untch, et al.
Breast (Edinburgh, Scotland)|October 22, 2011
Lessons from the neoadjuvant setting on how best to choose adjuvant therapiesGunter von Minckwitz, Sibylle Loibl, Andrea Maisch, et al.
Oncology Research and Treatment|December 9, 2014
Predictive factors for response to neoadjuvant therapy in breast cancerSibylle Loibl, Gunter von Minckwitz, Michael Untch, et al.
Oncology and Therapy|May 31, 2021
How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast CancerMichael Untch, Miguel Martin, Michelino De Laurentiis, et al.
Seminars in Oncology|June 8, 2004
Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropeniaLaura Biganzoli, Michael Untch, Tomas Skacel, et al.
Gynakologisch-Geburtshilfliche Rundschau|April 10, 2004
[Sentinel lymph node biopsy in breast cancer: state of the art]Ingo Bauerfeind, Isabelle Himsl, Thorsten Kühn, et al.
Pageof 38